TETRABENAZINE (tetrabenazine) by Bausch + Lomb is vesicular monoamine transporter 2 inhibitors [moa]. Approved for vesicular monoamine transporter 2 inhibitor [epc]. First approved in 2020.
Drug data last refreshed 19h ago
Vesicular Monoamine Transporter 2 Inhibitors
Vesicular Monoamine Transporter 2 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)
Worked on TETRABENAZINE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.